All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the GvHD Hub was pleased to speak to Carrie L. Kitko, Vanderbilt University Medical Center, Nashville, US. We asked, What is the latest update on biomarkers for assessing GvHD?
What is the latest update on biomarkers for assessing GvHD?
Kitko begins by explaining how treatment response at Day 28 is used as a surrogate marker for long-term outcomes in clinical trials, despite limited accuracy. Kitko then discusses the Mount Sinai Acute GvHD International Consortium (MAGIC) algorithm, which can be used to estimate a patient's probability of 6-month nonrelapse mortality. Finally, Kitko talks about potential new biomarkers that were discussed at the Tandem Meetings.
Monthly Theme | Predictive factors for GvHD
This month, the GvHD Hub are focusing on prognostic factors for Graft-versus-Host Disease (GvHD).
GvHD prophylaxis in mismatched, unrelated allogeneic stem cell transplant: a comparison of post-transplant cyclophosphamide and anti-thymocyte globulin
PtCy or ATG for GvHD prophylaxis in mismatched, unrelated allogeneic stem cell transplant
Subscribe to get the best content related to GvHD delivered to your inbox